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Abstract
Activated B-Cell (ABC) Diffuse Large B-Cell Lymphoma (DLBCL) is a common, aggressive and poorly chemoresponsive
subtype of DLBCL, characterized by constitutive canonical NF-kB signaling. Inhibition of NF-kB signaling leads to apoptosis
of ABC-DLBCL cell lines, suggesting targeted disruption of this pathway may have therapeutic relevance. The selective IKK
inhibitor, NEMO Binding Domain (NBD) peptide effectively blocks constitutive NF-kB activity and induces apoptosis in ABC-
DLBCL cells in vitro. Here we used a comparative approach to determine the safety and efficacy of systemic NBD peptide to
inhibit constitutive NF-kB signaling in privately owned dogs with spontaneous newly diagnosed or relapsed ABC-like
DLBCL. Malignant lymph nodes biopsies were taken before and twenty-four hours after peptide administration to
determine biological effects. Intravenous administration of ,2 mg/kg NBD peptide was safe and inhibited constitutive
canonical NF-kB activity in 6/10 dogs. Reductions in mitotic index and Cyclin D expression also occurred in a subset of dogs
24 hours post peptide and in 3 dogs marked, therapeutically beneficial histopathological changes were identified. Mild,
grade 1 toxicities were noted in 3 dogs at the time of peptide administration and one dog developed transient subclinical
hepatopathy. Long term toxicities were not identified. Pharmacokinetic data suggested rapid uptake of peptide into tissues.
No significant hematological or biochemical toxicities were identified. Overall the results from this phase I study indicate
that systemic administration of NBD peptide is safe and effectively blocks constitutive NF-kB signaling and reduces
malignant B cell proliferation in a subset of dogs with ABC-like DLBCL. These results have potential translational relevance
for human ABC-DLBCL.
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Introduction
Diffuse large B-cell lymphoma (DLBCL) represents a heterog-
enous group of malignancies that can be further divided into 3
distinct sub-types: Germinal Center B Cell- (GCB-), Activated B
Cell- (ABC-) and Primary Mediastinal B Cell- (PMBC-) DLBCL
based on the malignant cell of origin and defined gene expression
profiles [1–3]. ABC-DLBCL is the most aggressive and least
chemo-responsive subtype with a 5 year survival rate of ,40% [1].
ABC-DLBCL is characterized by constitutive canonical NF-kB
activity that drives lymphomagenesis through up-regulation of NF-
kB target genes that promote cellular proliferation (e.g. Cyclin D2)
and survival (e.g. XIAP, c-FLIP, and Bcl-2) [4–8]. This mechanism
contributes to the aggressive phenotype and chemo-resistance
frequently recognized in patients with ABC-DLBCL.
Many molecular aberrancies responsible for constitutive NF-kB
signaling in ABC-DLBCL and other hematological malignancies
have been identified [9]. Amongst the most frequently occurring
are oncogenic mutations in proteins of the BCR and TLR
signaling pathways such as CD79a, CARD11 and MyD88, which
result in constitutive IKK activity [1,10]. ABC-DLBCL cell lines
are dependent upon constitutive NF-kB signaling for their survival
and disruption of this pathway using small molecules inhibitors
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and dominant negative IkBa constructs leads to rapid apoptosis
[5,6].
The IKK complex is central to the activation of canonical NF-
kB and is composed of two catalytic subunits IKKa and IKKb
and a regulatory, ubiquitin binding subunit IKKc or NF-kB
essential modulator (NEMO) which has no catalytic function
[11,12]. IKKa and IKKb both contain a NEMO Binding Domain
(NBD) which interacts with the alpha helical domain of NEMO
[13]. When activated, the IKK complex phosphorylates inhibitory
IkB proteins, targeting them for ubiquitination and proteosomal
degradation. This allows IkB sequestered NF-kB family members
to translocate into the nucleus and initiate transcription of target
genes [8]. As many of the oncogenic mutations that drive
constitutive NF-kB activity in ABC-DLBCL occur upstream of
the IKK complex, functional disruption of this complex represents
an attractive universal strategy for the treatment of ABC-DLBCL
that arises from different oncogenic mutations [14].
NBD peptide is a 13 amino acid peptide that spans the NBD of
IKKa and IKKb [13,15]. It is a selective, non-catalytic inhibitor
of IKK that disrupts the interaction of the catalytic subunits with
NEMO, effectively blocking kinase activity that is triggered by
many different inflammatory stimuli [15]. Interestingly, NBD
peptide does not block basal NF-kB activity and following systemic
administration, it safely and effectively ameliorates disease in
multiple rodent models of acute and chronic inflammation [16–
20]. NBD peptide also inhibits constitutive NF-kB activity in
malignant cell lines derived from many different cancer types,
including ABC-DLBCL resulting in increased sensitization to
chemotherapeutic agents and increased apoptosis [21–26]. Given
these findings, NBD peptide may represent a safe and effective
therapy either alone or in combination with cytotoxic agents for
patients with treatment-naı̈ve or refractory ABC-DLBCL.
Pet dogs that develop Non-Hodgkins Lymphoma (NHL) are
recognized as a clinically relevant, spontaneous large animal
model of the human disease [25,27–31]. Gene expression analysis
of primary canine B cell lymphoma tissue has revealed germinal
center and post-germinal center, ABC-like DLBCL subsets with
the latter characterized by the presence of phosphorylated p65 and
increased expression of NF-kB target genes [29]. Furthermore,
tissue microarrays from lymphomatous canine tissue confirmed
the presence of constitutive NF-kB activity and pharmacological
inhibition of IKK leads to increased cytotoxicity in canine B cell
lines [28]. These data support our previous findings of constitutive
canonical NF-kB activity as defined by the presence of phosphor-
ylated IKK and IkBa within the malignant lymph nodes of dogs
with DLBCL [25]. Using this canine model, we have shown in vitro
that NBD peptide, fused to the cell penetrating Antennapedia
peptide (AntP) inhibits phosphorylation of IKK and IkBa in
primary malignant canine B cells and leads to rapid apoptosis [25].
Furthermore, local, intranodal administration of NBD peptide to
dogs with spontaneous ABC-like DLBCL effectively inhibits the
expression of NF-kB target genes within the malignant node and
decreases tumor burden [25]. In the present phase I clinical trial,
we sought to expand on these findings and determine whether
systemic, intravenous administration of NBD peptide is safe and
effective in inhibiting constitutive canonical NF-kB signaling in
lymphomatous tissue of dogs with spontaneous ABC-like DLBCL.
Materials and Methods
Reagents and cell lines
NBD peptide was synthesized and purified by Dr. James I.
Elliott (at the Howard Hughes Medical Institute Biopolymer-Keck
Foundation Biotechnology Resource Laboratory, Yale University,
New Haven, CT) using standard tertbutoxycarbonyl (t-Boc)
chemistry, cleavage with hydrofluoric acid, and purification by
reversed-phase HPLC [26]. TNFa was purchased from Sigma-
Aldrich (Saint Louis, MO). The human GCB-DLBCL cell line
SUDHL-6 and the ABC-DLBCL cell line OCI-Ly10 were
obtained from Dr Anne Novak (Mayo Clinic Cancer Center,
Rochester, Mn).
Clinical trial study population, eligibility criteria and study
design
The clinical trial protocol was fully approved by the University
of Pennsylvania’s Institutional Animal Care and Use Committee
(Privately Owned Animal Protocol number: 803765). Only dogs
with full written informed owner consent were eligible for
enrollment. Pet dogs with newly diagnosed (treatment-naı̈ve) or
relapsed stage III or greater, lymphoma were eligible for screening
if they were systemically well (as determined by clinical examina-
tion, blood screening (complete blood counts (CBC) and Chem-
istry Screen (CS) and urinalysis (UA)), had a PCV.30%, an
ECOG performance ,1, a life expectancy of .2 months and had
not received systemic chemotherapy within the last 3 weeks or
prednisone therapy within the last 72 hours. All dogs underwent
lymph node excision or biopsy to confirm the diagnosis of DLBCL
by histopathology and flow cytometric phenotyping and to
determine the presence of constitutive NF-kB activity. The
histopathological diagnosis of DLBCL and cytological confirma-
tion of large B cell lymphoma were made by board certified
veterinary pathologists (M.G., and A.D., see acknowledgements)
and by a board certified clinical pathologist (R.P.) respectively.
Only dogs with DLBCL and constitutive NF-kB activity within
their malignant lymph nodes as determined by the presence of
phospho-IKK, phospho-IkBa and phospho-p65 were eligible to
receive NBD peptide.
Tumor burden was calculated by measuring three dimensions
(length, width and height) for each malignant lymph node. The
mass of each node was calculated as previously described and the
sum of measured lymph node mass was considered as total tumor
mass [25]. Response to NBD peptide was evaluated according to
the Veterinary Cooperative Oncology Group criteria for assess-
ment of response in peripheral nodal lymphoma, adapted for use
in dogs from the published RECIST criteria [32]. The Veterinary
Cooperative Oncology Group Common Terminology for Adverse
Events, version 1.0 was used to grade adverse events [33].
In vivo NBD peptide treatment
In this phase I dose escalation clinical trial, both treatment-
naı̈ve and relapsed dogs were enrolled. NBD peptide was
administered according to a standard 3+3 trial design. The dose
endpoint was the dose at which canonical NF-kB signaling was
inhibited within malignant lymph nodes. Peptide was reconstituted
to 50 mM in sterile DMSO and diluted in 20 mls of lactated
Ringers solution immediately prior to intravenous administration
at a constant rate of 20 ml/hr. Twenty-four hours post NBD
peptide administration, excisional or Tru-cut biopsies of a
peripheral malignant lymph node were taken for Western blot,
qRT-PCR and histopathological analysis. Following the post-
treatment biopsy, dogs received induction or rescue chemotherapy
as determined by their primary attending veterinary oncologist
and a short course of prophylactic antibiotics (amoxicillin). All
dogs received a follow-up full clinical examination, CBC, CS and
urinalysis one week post NBD peptide.
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Pharmacokinetics
EDTA anti-coagulated blood samples were taken at 0, 30, 60,
90, 120, 240, 360 mins and 24 hours post infusion. Plasma was
separated by centrifugation and stored at 280uC prior to
pharmacokinetic analysis. Mass spectrometer analysis of NBD
peptide in plasma samples was performed by Frontage Labora-
tories, Exton, PA and pharmacokinetic (PK) parameters were
determined using WinNonlin v5.2 software. The lower limit of
quantification (LLOQ) was set to 10 ng/ml however, in some
instances the LLOQ was changed to 20 ng/ml because of
potential interference in the samples.
Flow cytometry
Lymphomas were phenotyped using a combination of the
following antibodies: Fluorescein isothiocyanate (FITC)-conjugat-
ed rat anti-canine CD3 (Serotec, Raleigh NC), Phycoerythrin
(PE)-conjugated mouse anti-canine CD21-like molecule (Serotec),
allophycocyanin (APC)-conjugated mouse anti-human CD79a
(BD Biosciences, San Jose, CA), and APC-conjugated mouse
anti-canine CD45. For CD79a staining, cells were fixed with 1%
paraformaldehyde and permeabilized with 0.1% saponin before
staining. Cells were acquired on a FACSCalibur cytometer (BD
Biosciences) and analyzed using FlowJo software (TreeStar).
Western blot analyses
Lymph node biopsy samples were mechanically dissociated in
RPMI and red blood cells were removed using ACK lysis buffer
(Gibco) according to manufacturer’s instructions. Cells were lysed
in 50 mM Tris-HCL containing 1% NP-40, 150 mM NaCl,
2.5 mM EDTA, 5% glycerol, a 1:50 dilution of Protease Inhibitor
Cocktail and 1:50 dilutions of Phosphatase Inhibitor Cocktails 2
and 3 (Sigma-Aldrich, Saint Louis, MO). Samples were centri-
fuged and protein concentrations were determined by micro BCA
assay (Thermo Scientific, Rockford, IL). Proteins from whole cell
extracts were separated by SDS-PAGE (10%) followed by transfer
to PVDF membrane. Membranes were probed with polyclonal
rabbit anti-human antibodies against phospho-IKKa/b (16A6),
IKKb (L570), phospho-IkBa (14D4), mouse anti-human IkBa
(L35A5) and b-actin (4967) (Cell Signaling, Danvers, MA). An
HRP-conjugated donkey anti-rabbit or anti-mouse IgG was used
as the secondary detection antibody (Amersham, Piscataway, NJ).
Blots were developed using ECL Plus (Amersham, Piscataway,
NJ). Densitometry was performed using ImageJ software and
integrated density values for each band were obtained using the
Analyze Particles function [34].
Quantitative Reverse Transcription PCR (qRT-PCR)
Lymph node biopsies were immediately placed in RNAlater
(Ambion, Austin, TX) and stored at –80uC prior to RNA
extraction. Total RNA extraction was performed using the
RNeasy Mini Kit (Qiagen, Valencia, CA). Reverse transcription
was performed using random hexamers and Superscript II reverse
transcriptase (Invitrogen Corp., Carlsbad. CA, USA) according to
the manufacturer’s instructions. Primer sequences for canine A1,
A20, Bcl-XL, c-FLIP, Cyclin D1, Bcl-2, XIAP and b-actin have
been previously described [25,35]. Primers were synthesized by
Invitrogen Corp. Real-time PCR assays were performed using
SYBR Green (Fermentas, Glen Burnie, Maryland). Samples were
run in triplicate using standard conditions on an ABI 7500
sequence detector (Applied Biosystems, Carlsbad, CA) and data
were analyzed using b-actin as an endogenous control. Dissoci-
ation curves were performed after each experiment to confirm the
specificity of product amplification. Statistical analysis was
performed using a two-tailed Student’s ‘t’ test where statistical
significance = p,0.05.
Immunohistochemistry (Ki67, IRF4 and TUNEL staining)
Immunohistochemical analysis was performed on 5 micron
sections of formalin fixed paraffin embedded lymph node tissue
from dogs with spontaneous DLBCL using a DAKO automatic
universal staining system. Sections were heated in a 60uC oven for
1 hour, depararaffinized in PRO PAR clearant and rehydrated in
progressively decreasing grades of ethanol. Antigen retrieval was
performed by boiling sections in sodium citrate buffer, pH ,9.0
for 15 minutes. Endogenous peroxidase was blocked with 3%
hydrogen peroxide. For Ki67 staining, a 1:50 dilution of a
monoclonal mouse anti-human antibody (Clone MIB-1, DAKO)
was used and immunodetection was performed using a biotiny-
lated goat anti-rabbit/anti-mouse immunoglobulin and SA-HRP
(LSAB2 kit, DAKO, Carpinteria, CA). For IRF-4 staining, a 1:200
dilution of a polyclonal mouse anti human antibody (DAKO,
M7259) was used and immunodetection was performed using a
peroxidase polymer conjugated anti-mouse secondary antibody
system (ImmPRESS Anti-mouse Ig peroxidase polymer detection
kit). In all cases, antibody binding was detected using 3,39-
diaminobenzidine solution and tissues were counterstained with
hematoxylin. Slides were viewed using a Nikon E600 infinity
corrected upright microscope. Bright field images were acquired
using a Nikon Digital Sight DS-Fi1 color camera using NIS-
Element BR3.0 for image analysis. For TUNEL staining, formalin
fixed, paraffin embedded tissue sections were de-waxed, rehydrat-
ed and permeabilized in 10 mM sodium citrate buffer. Apoptotic
cells were detected using the cell death detection kit (Roche,
Indianapolis, IA) following the manufacturer’s instructions. Nuclei
were counterstained with DAPI, and slides were mounted with
ProLong Antifade (Invitrogen) prior to visualization.
Results
Constitutive canonical NF-kB activity is present in dogs
with B cell lymphoma
Eleven dogs with spontaneous DLBCL that fulfilled all eligibility
criteria were enrolled following owner consent in this phase I pre-
clinical feasibility trial. Patient characteristics are shown in Table
S1. At the time of presentation, all dogs were diagnosed with stage
III or greater, substage a, lymphoma. Using both histopathology
and flow cytometry, all dogs were confirmed to have intermediate
to high grade DLBCL, except for one dog where insufficient tissue
was obtained to allow histopathological classification. This case
was confirmed as having large B cell lymphoma by flow cytometry
and cytological analysis. In all cases evaluated by histopathology
the normal lymph node architecture was destroyed by sheets
of neoplastic lymphocytes and the number of mitoses ranged from
3–7 per high power field (intermediate grade) or 8–12 per high
power field (high grade) (Table S1).
To confirm the presence of constitutive canonical NF-kB
activity within malignant lymph nodes, Western blot was
performed on whole cell extracts prepared from malignant
peripheral lymph node biopsies. All dogs screened had evidence
of p-IKK, p-IkBa and p-p65 in their malignant nodes (Fig. 1A).
These findings were consistent with those of the human ABC-
DLBCL cell line Ocl-Ly3 which exhibits constitutive NF-kB
activity [5] and of TNF-a activated canine PBMCs (positive
canine control) (Fig. 1A). In contrast, in the human GCB-DLBCL
cell line SUDHL-6 which does not exhibit constitutive NF-kB
activity [5] and resting canine PBMCs, p-IKK, p-IkBa and p-p65
were not detected (Fig. 1A). Densitometry was performed to
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quantify phosphorylation of IKK and p65 (Fig. 1B and C). All
dogs showed p-IKK:IKK ratios similar to or greater than TNF-a
activated PBMCs. Although no dog exhibited pIKK:IKK ratios
greater than Ocl-Ly3, seven out of eleven dogs showed greater or
equal p-p65:b-actin ratios compared to Ocl-Ly3. Interestingly,
although all eligible dogs demonstrated evidence of constitutive
canonical NF-kB activity in malignant lymph node biopsies,
suggesting an ABC phenotype, none of the malignant canine
lymph nodes stained positive for MUM1/IRF-4, an NF-kB target
gene that is over-expressed in ABC-DLBCL and a hallmark of this
subtype in humans (data not shown). Based on these results, all
enrolled dogs were considered to have ‘‘ABC-like’’ DLBCL.
Systemic administration of NBD peptide is safe and has
minimal effects on hematological and biochemical
parameters
In this phase I, 3+3 standard dose escalation study, three dogs in
Group 1 received 0.5 mg/kg NBD peptide, seven dogs in Group 2
received 1 mg/kg NBD peptide and one dog in Group 3 received
2 mg/kg NBD peptide. NBD peptide was administered as a slow
intravenous infusion over 1 hour. During infusion, two dogs in
Group 1 became drowsy and developed moderate tachycardia and
hypertension (Table S1). These effects were mild and transient and
resolved without treatment when the infusion was discontinued.
The remaining dogs were premedicated with the serotonin 5-HT3
receptor antagonist ondansetron and the H1 receptor antagonist
diphenhydramine. Transient hypertension was identified in one
additional dog in Group 2. Pharmacokinetic analysis showed
detectable albeit low levels of NBD peptide in plasma samples of
8/10 dogs within 60 minutes of infusion (Table S2). Peptide was
not detected in the plasma of any dog after 60 mins.
Hematological and biochemical parameters were evaluated for
all dogs immediately before and one week after NBD peptide plus
induction or rescue chemotherapy (Fig. S1). There were mild
decreases in hematocrit (9/11 dogs) and lymphocyte counts (9/11
dogs) and an increase in platelet count (8/11 dogs) post
combination treatment. However, in most cases post treatment
values remained within the normal range. In dogs with elevated
ALKP values prior to NBD peptide administration (4/11 dogs; all
previously treated for relapsed lymphoma), further increases in
ALKP were seen post treatment. One dog in Group 2 with normal
serum biochemical parameters at the time of treatment and who
received L’asparaginase 24 hrs after peptide administration,
showed significant but asymptomatic increases in liver values
(ALT, ALKP, AST and GGT) one week later (Fig. S1). The dog
received no specific treatment and liver values returned to baseline
two weeks later (data not shown). For this reason, 3 more dogs
were recruited to Group 2 before further dose escalation. No other
dog showed significant biochemical abnormalities following
treatment.
Figure 1. Constitutive canonical NF-kB activity is present in dogs with large B cell lymphoma. A. Whole cell extracts from malignant
lymph node biopsies were analyzed by immunoblot for the presence of phospho-IKKa/b, IKKb, phospho-IkBa, IkBa, phospho-p65 and b-actin. WCE
from TNF-a activated canine PBMCs and from the human ABC-DLBCL cell line Ocl-Ly3 were used as positive controls and WCE from unstimulated
canine PBMCs and the GCB-DLBCL cell line SUDHL-6 were used as negative controls. Integrated densitometry was used to quantify amounts of
phospho-IKKa/b and IKKb and phospho-p65 and b-actin. Relative canonical NF-kB activity in each sample was expressed as B. phospho-IKKa/b:IKKb
and C. phospho-p65:b-actin. The horizontal line in B and C marks the phosphorylation status of IKKa/b and phospho-p65 respectively in TNF-a
activated canine PBMCs.
doi:10.1371/journal.pone.0095404.g001
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NBD peptide inhibits constitutive canonical NF-kB
signaling in malignant lymph nodes
To determine whether NBD peptide can inhibit constitutive
canonical NF-kB signaling in vivo, biopsies of malignant lymph
nodes were taken before and 24 hours after intravenous peptide
administration, prior to induction or rescue chemotherapy.
Previous mouse studies have demonstrated inhibitory effects of
NBD peptide on NF-kB activity occurring between 24 and
48 hours after systemic administration [17,18,36]. The effects of
NBD peptide on the phosphorylation status of IKK and IkBa
were determined by immunoblot (Fig. 2A). To correct for any
unequal sample loading, ratios of pIKK:IKK and pIkBa:IkBa
were determined in pre- and post-peptide biopsy samples using
integrated densitometry. Paired samples from ten of the eleven
treated dogs were available for analysis (Fig. 2A). Six out of ten
dogs showed reductions in the phosphorylation status of IKK (2 in
Group 1 and 4 in Group 2) and 4 dogs showed an increase in IKK
phosphorylation (3 in Group 2 and 1 in Group 3) 24 hours post
peptide. Changes in phosphorylation status of IkBa generally
reflected the observed change in IKK phosphorylation (Fig. 2C).
Bands for p-IKK and IkBa were not detectable for the post
treatment sample of dog 2, however p-IkBa:b-actin ratio was
reduced in the post sample compared to pre-sample (data not
shown). In all other dogs, the effects of NBD peptide on p-IKK:b-
actin and p-IkBa:b-actin correlated well with effects on pIK-
K:IKK and pIkBa:IkBa (data not shown).
Based on evidence of biological activity of NBD peptide when
administered at 1 mg/kg, no clear dose dependent effect on
inhibition at 2 mg/kg, and the significant cost of peptide
administration at doses greater than 1 mg/kg no further dose
escalation was performed.
NBD peptide inhibits proliferation and induces apoptosis
in a subset of dogs with spontaneous DLBCL
Constitutive canonical NF-kB signaling contributes to lympho-
magenesis by driving cellular proliferation and inhibiting apopto-
sis. Therefore to determine the effects of NBD peptide on cellular
proliferation and apoptosis the histopathological features of lymph
node biopsies taken pre and 24 hours post peptide treatment were
compared. Paired tissue samples were available for histopatholog-
ical analysis from nine of the eleven dogs. In 3 dogs, post treatment
samples had notably fewer mitotic figures, increased numbers of
apoptotic bodies and tingible body macrophages and exhibited
malignant cell shrinkage, nuclear pyknosis and fragmentation
when compared to pre-treatment biopsies (Fig. 3). To quantify the
effect of NBD peptide on malignant cell proliferation, pre- and
24 hours post-peptide treatment biopsy samples were evaluated
for expression of the proliferation marker Ki67 by IHC (Fig. 4A
and B). Four dogs showed a statistically significant reduction in the
number of Ki67+ cells following NBD peptide treatment. Dog 6
also showed a reduction in mitotic index however the post
treatment biopsy sample was too small to evaluate 10 high-
powered fields and so statistical significance could not be
determined. To determine whether NBD peptide inhibited the
expression of Cyclin D1, qRT-PCR was performed on pre- and
24 hour post-peptide biopsy samples. Eight out of eleven dogs
showed a decrease in the expression of Cyclin D1 following NBD
peptide treatment (Fig. 4C) and 4 of these dogs also had a
reduction in Ki67 mitotic index.
Figure 2. Systemic administration of NBD peptide inhibits IKK and IkBa phosphorylation in malignant lymphoid tissue. Biopsies of
malignant lymph nodes taken before (pre-) and 24 hours after (post-) NBD peptide administration were evaluated for the presence of phospho-IKKa/
b and phospho-IkBa by immunoblot. A. Immunoblots for phospho-IKKa/b and IKKb and phospho-IkBa and IkBa. Immunoblots were evaluated by
densitometry and the ratios of B. phospho-IKKa/b:IKKb and C. phospho-IkBa:IkBa were calculated. ND (Not Determined).
doi:10.1371/journal.pone.0095404.g002
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Effects of NBD peptide on cellular apoptosis and tumor
burden
The expression of six pro-survival NF-kB target genes (A1, c-
FLIP, XIAP, Bcl-XL, Bcl-2 and A20) were evaluated by qRT-PCR
in malignant lymph nodes before and 24 hours after NBD peptide
administration (Fig. 5). In 6 out of 11 dogs, the expression of 3 or
more target genes was reduced following peptide administration.
Although there was no apparent dose-dependent effect of NBD
peptide on other measured parameters in the one dog that
received 2 mg/kg NBD peptide (dog 11), it was noted that this dog
showed the most significant inhibition of NF-kB target genes. To
determine whether NBD peptide treatment increased apoptosis,
TUNEL staining was performed on pre- and post-peptide biopsy
samples (Fig 6A). Tissue was available from 9 dogs. Five dogs
showed a trend towards an increase in apoptosis following
treatment (Fig 6B). Although there was no clear correlation
between inhibition of pro-survival gene expression and apoptosis,
4 of the dogs that showed an increase in apoptosis also showed
statistically significant reductions in Ki67 index (Fig. 4B). There
was no correlation between NBD peptide dose and apoptosis.
To determine whether NBD peptide reduced tumor burden,
malignant lymph nodes were measured immediately before and
24 hours after NBD peptide administration. Three dimensions
were measured for each node and the node mass was calculated as
previously described [25]. The sum of peripheral lymph node mass
was considered as measureable tumor mass. The same lymph
nodes were evaluated 24 hours post NBD peptide and the
change in measureable tumor mass was calculated (Fig. 6C).
Measurements were available for 10 treated dogs. Five out of 10
dogs showed greater than 20% reduction in measureable tumor
mass following peptide administration. Seven dogs in this phase I
study achieved clinical remission (CR) following NBD peptide plus
chemotherapy including 5 dogs treated at the time of their first
relapse. All dogs that achieved CR showed evidence of either p-
IKK inhibition or Cyclin D1 inhibition (Table S3). The four dogs
that did not achieve clinical remission experienced either poor
response to initial chemotherapy or were presenting at the time of
second or third relapse and were multi-drug resistant. While NBD
peptide treatment lead to Ki67 and Cyclin D inhibition in three of
these dogs, a single dose of NBD peptide was insufficient to induce
CR.
Discussion
Many of the genetic mutations that drive lymphomagenesis via
constitutive NF-kB activation in ABC-DLBCL occur upstream of
the canonical heterotrimeric IKK complex containing IKKa,
IKKb and NEMO. Therefore, specifically targeting this complex
may provide therapeutic benefit for patients with ABC-DLBCL
regardless of the specific mutation that disrupts signal regulation.
Evaluation of small molecule ATP-binding site inhibitors of IKKb
re-inforces this concept although off-target side effects together
with the compensatory activity of IKKa homodimers observed in
the presence of IKKb inhibition may reduce their therapeutic
efficacy [37,38]. In contrast, NBD peptide binds to and inhibits
association of NEMO with IKKa and IKKb making its inhibitory
effect specific for the IKK complex.
In this study we recruited dogs with evidence of constitutive
canonical NF-kB activity in their malignant lymph nodes as
determined by the presence of phosphorylated IKK, IkBa and
p65. While all dogs screened had evidence of canonical NF-kB
activity according to these criteria, suggesting an ABC-like
phenotype, none of the canine tumors expressed MUM-1/IRF-
4, a hallmark feature of ABC-DLBCL in humans [2,5]. In human
ABC-DLBCL over-expression of IRF-4 is driven by constitutive
NF-kB activity and operates in a feedback loop to reinforce
constitutive NF-kB signaling. Our results therefore suggest that the
downstream effectors of NF-kB activity that drive lymphomagen-
esis may differ between species. These findings and conclusions are
supported by recent gene expression profiling studies of canine B
cell lymphomas [29]. Interestingly, data from human DLBCL cell
lines indicates that nuclear p65 and cytoplasmic p-IkBa are also
present in GCB cell lines and that this may result from constitutive
activity of the non-canonical pathway leading to stabilization of
NIK [39]. Constitutive activation of both canonical and non
canonical NF-kB pathways has recently been demonstrated in
canine lymphoma although the mechanisms leading to this activity
are as yet undetermined [28].
The aim of this study was to determine the safety and
biologically effective dose of systemically administered NBD
peptide in dogs with ABC-like DLBCL. Our results show that
there were no significant acute or chronic toxicities identified at
any NBD peptide dose evaluated (0.5–2.0 mg/kg) either by
clinical or hematological and biochemical parameters and all dogs
survived for at least one month after treatment. One dog did
develop transient biochemical abnormalities that were consistant
with hepatotoxic damage. This dog also received L9asparaginase
which, although not reported in dogs, causes hepatocellular
enzyme elevations and subclinical hepatopathy in humans. In all
dogs, mild reductions in lymphocyte counts were detected one
week after NBD peptide plus chemotherapy. We have previously
shown that NBD peptide has minimal effect on peripheral B cells
Figure 3. Effect of NBD peptide on malignant lymph node
histopathology. Biopsies of malignant lymph nodes taken before
(pre-) and 24 hours after (post-) NBD peptide adminsitration were
stained with H&E and evaluated by light microscopy. Sections were
evaluated for the presence of mitotic figures, cellular shrinkage, nuclear
pyknosis, apoptotic bodies and tingible body macrophages. Arrows
indicate mitotic figures, arrowheads indicate pyknotic nuclei and
cellular shrinkage. Representative sections of three dogs are shown
(406magnification).
doi:10.1371/journal.pone.0095404.g003
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Figure 4. NBD peptide inhibits malignant cell proliferation and Cyclin D expression in a subset of dogs with ABC-like DLBCL A.
Malignant lymph node tissue sections taken before (pre-) and 24 hours after (post-) NBD peptide treatment were evaluated for expression of Ki67 by
IHC. B. 10 high power fields were evaluated for Ki67 positive cells in each pre- and post-NBD peptide tissue section. The average number of Ki67
positive cells per high power field (hpf) was determined. C. Quantitative RT-PCR analysis of CyclinD expression in malignant tumor samples post-NBD
peptide. The relative quantification of gene expression in post treatment samples was normalized to pre-treatment values for each dog. All assays
were performed in triplicate and b-actin was used as an endogenous control. wp,0.05, wwp,0.005, ND (Not Determined).
doi:10.1371/journal.pone.0095404.g004
Figure 5. NBD inhibits the expression of canonical NF-kB target genes in a subset of dogs with ABC-like DLBCL. NF-kB target gene
expression within malignant lymph node tissues before and 24 hours after NBD peptide administration was determined by qRT-PCR. The relative
quantification of gene expression in post treatment samples was normalized to pre-treatment values for each dog. b-actin was used as an
endogenous control and all assays were performed in triplicate. p values are calculated on dCt data, wp,0.05, wwp,0.005.
doi:10.1371/journal.pone.0095404.g005
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and consider it likely that these changes are associated with
concurrent chemotherapy rather than peptide-induced B or T cell
apoptosis [25]. While this safety data relates only to a single dose of
peptide, cummulative toxicities following repeat dosing are
unlikely to occur given the short half life of the peptide and the
available safety data on multi-dose administration in rodents.
Following peptide administration and chemotherapy 7 dogs
achieved durable clinical remissions and three of these dogs
survived greater than 16 months (Table S1). Two relapsed dogs
(dogs 4 and 6) were treated with the same chemotherapeutic
agents following NBD peptide as they had been resistant to before
peptide administration. In these cases, the single dose of NBD
peptide did not appear to reverse chemoresistance and induce a
CR. However, it is likely that NBD peptide will need to be
administered more than once to reverse resistance and lead to an
improved clinical response. Further placebo controlled clinical
trials will be required to determine whether NF-kB inhibition
synergizes with chemotherapy to prolong time to progression and
overall survival in dogs with DLBCL [28].
In vivo studies in rats, mice and piglets have evaluated NBD
peptide at doses ranging from 0.75 mg/kg to 20 mg/kg and have
demonstrated that following intraperitoneal, intranasal, intracra-
nial and topical administration NBD peptide has therapeutic
effects at distant sites [15,17–19,40–44]. In all instances, systemic
administration of NBD peptide was well tolerated and showed no
cytotoxic effects in the majority of tissues analysed [45,46]. These
findings suggest that the drug has good absorption and tissue
distribution kinetics. In this study, as a consequence of drug
expense and evidence of biological activity at 0.5–2.0 mg/kg, the
maximum tolerated dose of NBD peptide in dogs was not reached
and it is possible that higher doses of peptide would result in
greater NF-kB inhibition. Pharmacokinetic data obtained during
this study indicate that at the doses studied plasma concentrations
of NBD peptide were very low and in all cases undetectable 1 hour
post administration. Given that effective inhibition of canonial NF-
kB activity occurred in some dogs, it is most likely that the
observed plasma clearance is associated with rapid tissue uptake of
peptide rather than rapid elimination.
We found that 24 hours after systemic administration, low doses
(,2.0 mg/kg) of NBD peptide inhibited IKK phosphorylation
and decreased malignant cell proliferation in dogs with the highest
ratios of p-p65:b-actin at enrollment (Table S3). There was no
apparent dose effect. Similar results were obtained when NBD
peptide was administered via direct intranodal injection into
malignant canine lymph nodes [25]. Five of the dogs with high
ratios of p-p65:b-actin at enrollment achieved a complete
remission following NBD peptide and chemotherapy. These
results suggest that NBD peptide is effective in inhibiting canonical
NF-kB activity in dogs with DLBCL at doses ranging from 0.5–
2.0 mg/kg and that dogs whose tumors have high levels of NF-kB
activity (as determined by high p-p65:b-actin) are most likely to
respond [47]. Different subsets of ABC-DLBCL have been
distinguished in humans based on their expression of STAT3
and the degree of NF-kB activity as determined by gene expression
profiling [47]. It is possible that similar subsets of ABC-like
DLBCL occur spontaneously in dogs and that this influences their
response to IKK inhibitors. In the absence of definining, subtype-
specific phenotypic markers further gene expression analysis would
be required to determine whether variations in response to NBD
peptide are truly associated with different ABC-DLBCL subtypes.
Indeed, future studies will be required to accurately detect those
patients (both human and canine) that exhibit high levels of NF-kB
activity within their tumors and determine whether this correlates
with biological and clinical response to IKK inhibitors such as
NBD peptide. In cases with high levels of NF-kB activity, higher
doses of NBD peptide or the concurrent use of synergistic pathway
Figure 6. NBD peptide promotes apoptosis and reduces tumor burden in a subset of dogs with ABC-like DLBCL. A. Malignant lymph
node tissue sections taken before (pre-) and 24 hours after (post-) NBD peptide treatment were stained using TUNEL and counterstained with DAPI.
B. Apototic cells were counted in 10 high power fields and the average number of positive cells was determined for both pre- and post-treatment
sections. C. Calculated percent decrease in tumor mass 24 hours after NBD peptide treatment. Measureable tumor burden was determined pre and
24 hours post NBD peptide treatment and the percentage change in tumor burden was calculated. ND (Not Determined).
doi:10.1371/journal.pone.0095404.g006
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inhibitors, such as Jak/STAT inhibitors may provide greater levels
of inhibition and therapeutic benefit.
Interestingly, one dog that did not have a high ratio of p-p65:b-
actin at enrollment (dog 3), also showed biological effects of NBD
peptide within malignant tissue including decreased IKK phos-
phorylation, decreased Ki67 index, inhibition of Cyclin D1
expression, increased TUNEL staining and clear histopathological
changes consistant with increased cell death. This result would be
consistant with NBD mediated inhibition of an IKK dependent,
NF-kB independent pathway that is important for cell survival
[28]. Unexpectedly, the four dogs with the lowest ratios of p-
p65:b-actin at enrollment showed an increase in p-IKK:IKK
ratios following peptide treatment. It is possible that this may be
due to the previously reported small transient increase in IKK
activity observed in resting cells following NBD treatment [15].
However, consistent with the overall inhibition of NF-kB signaling
by NBD peptide, increased p-IKK levels did not negatively effect
clinical outcome as three of these dogs showed a reduction in
tumor volume and two experienced clinical remission following
combination peptide and chemotherapy.
In summary, NBD peptide delivered intravenously to dogs is
safe and effective at inhibiting constitutive canonical NF-kB
activity in a subset of dogs that exhibit the highest p-p65:b-actin
within their tumors. Futher studies are required to reliably identify
dogs with ABC-DLBCL that are likely to respond to NF-kB
inhibition and to determine whether repeat doses of NBD peptide,
administered in combination with systemic chemotherapy to dogs
with relapsed, refractory ABC-like DLBCL will have substantial
therapeutic benefit. The results of these studies may have
important translational relevance to human patients with ABC-
DLBCL.
Supporting Information
Figure S1 Changes in hematological and biochemical parame-
ters following NBD peptide administration. Hematology and
serum biochemistry were performed before (Pre-) and one week
after (Post-) NBD peptide administration. The bracket depicts
reference range values for each parameter. Dashed lines represent
dogs in Group 1, solid lines represent dogs in Group 2 and the
dotted line represents the one dog in Group 3.
(TIF)
Table S1 Signalment, disease characteristics and outcome of
clinical trial patients.
(TIF)
Table S2 Pharmacokinetic analysis of NBD peptide following
intravenous administration. ND = Not Determined.
(TIF)
Table S3 Summary of effects of NBD peptide on treated dogs. X
indicates dogs that showed the changes listed in the first column.
(TIF)
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